Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.

Emma K Flanagan Ralley E PrenticeEmily K WrightPeter R GibsonAlyson L RossJakob BegunMiles P SparrowRimma GoldbergOurania RosellaMegan BurnsKaterina V KiburgSally J Bell

Published in: Alimentary pharmacology & therapeutics (2021)

Ustekinumab drug levels appear stable in pregnancy, with a delivery infant:maternal ratio similar to that of anti-TNFs. Infant ustekinumab clearance was complete by 20 weeks post-partum, however, infants exposed in utero should avoid live vaccination before 12 months of age until further clearance data are obtained.

Keyphrases

pregnancy outcomes
pregnant women
preterm birth
birth weight
gestational age
emergency department
body mass index